Oncogenic Role of eIF-5A2 in the Development of Ovarian Cancer

Xin-Yuan Guan,1 Jackie M-W. Fung,1 Ning-Fang Ma,1 Sze-Hang Lau,1 Lai-Shan Tai,1 Dan Xie,1 Yu Zhang,2 Liang Hu,1 Qiu-Liang Wu,3 Yan Fang,3 and Jonathan S. T. Sham1

1Department of Clinical Oncology, The University of Hong Kong, Hong Kong; 2Laboratory of Medical Genetics, Harbin Medical University, Harbin; and 3Cancer Institute, Sun Yat-sen University, Guangzhou, People’s Republic of China

ABSTRACT

Amplification of 3q26 is one of the most frequent chromosomal alterations in many solid tumors, including ovarian, lung, esophageal, prostate, breast, and nasopharyngeal cancers. A candidate oncogene to eukaryotic initiation factor 5A2 (eIF-5A2), a member of eukaryotic initiation factor 5A subfamily, has been isolated from a frequently amplified region at 3q26.2. In this work, the tumorigenic ability of eIF-5A2 was demonstrated by anchorage-independent growth in soft agar and tumor formation in nude mice. Furthermore, antisense DNA against eIF-5A2 could inhibit cell growth in ovarian cancer cell line UACC-1598 with amplification of eIF-5A2 in form of double minutes. Cell growth rate in UACC-1598 was also inhibited when the expression level of EIF-5A2 was decreased by the reduction of the copy number of double minutes. The correlation of eIF-5A2 overexpression and clinical features of ovarian cancer was investigated using tissue microarray, and the result showed that eIF-5A2 overexpression was significantly associated with the advanced stage of ovarian cancer. These findings suggest that eIF-5A2 plays important roles in ovarian pathogenesis.

INTRODUCTION

Ovarian cancer is the leading cause of death from female gynecologic malignancies in developed countries, and its incidence has been increasing in Asian countries such as China and Singapore recently (1). Because of its insidious onset, 70% of ovarian cancer patients were diagnosed at advanced stage, and the prognosis is very poor with a 5-year survival rate of <20% (2). Recurrent chromosomal changes in ovarian cancer have been well studied by comparative genomic hybridization and amplification of 3q26 is one of the most frequent alterations (3–6). Amplification of 3q26 has been also frequently detected in lung cancer (7), esophageal cancer (8), prostate cancer (9), breast cancer (10), and nasopharyngeal cancer (11). These studies suggest that 3q26 may contain one or more putative oncogenes, which play important roles in the development or the progression of various solid tumors, including ovarian cancer.

Recently, we have isolated a candidate oncogene eukaryotic initiation factor 5A2 (eIF-5A2) from 3q26.2 using chromosome microdissection and hybrid selection (12). Sequencing analysis showed that eIF-5A2 shares a significant sequence homology (126 of 153, 82% amino acid identity) to eukaryotic initiation factor 5A (eIF-5A), including the domain needed for hypusine modification and the lysine 50 residue where the hypusine residue can be formed by posttranslational modification. Previous study showed that intracellular depletion of eIF-5A could cause the inhibition of cell growth (13). Other studies indicated that the inhibition of deoxypseudouridine synthase, the enzyme involved in the hypusination reaction of eIF-5A, could inhibit Chinese hamster ovary cells proliferation (14), suppress the growth of HeLa cells, and v-src-transformed NIH3T3 cells (15), and induce apoptosis (16). The proliferation-related function of eIF-5A supports that eIF-5A2 is a candidate oncogene related to the development of ovarian cancer. Amplification and overexpression of eIF-5A2 have been frequently detected in primary ovarian cancers and ovarian cancer cell lines (12, 17). Recently, Clement et al. (18) showed that eIF-5A2 has an important role in eukaryotic cell survival. In this study, the tumorigenicity of eIF-5A2, the oncogenic role of eIF-5A2 in signaling pathway, and the association between eIF-5A2 overexpression and clinical features of ovarian cancer were investigated.

MATERIALS AND METHODS

Tumorigenic Ability of eIF-5A2. Mouse fibroblast cell line NIH3T3 was obtained from the American Type Culture Collection. Human liver cell line LO2 was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, People’s Republic of China). To evaluate the tumorigenic ability of eIF-5A2, eIF-5A2 was cloned into expression vector pcDNA3.1(+) (Invitrogen, Carlsbad, CA) and transfected into NIH3T3 cell and LO2 cell independently using Lipofectamine (Life Technologies, Inc., Gaithersburg, MD) according to the manufacturer’s instructions. Stable EIF-5A2-expressing clones were selected using Geneticin (Life Technologies, Inc.) at a concentration of 800 μg/ml, and the expression level of eIF-5A2 in each clone was determined by Northern blot analysis.

Soft agar assay was carried out by suspending 1 × 104 cells in 0.4% Seaplaque agar (BioWhittaker Molecular Applications, Rockland, ME) in DMEM supplemented with 10% FBS and seeded onto solidified 0.6% agar in a 6-well plate. The cells were replenished with fresh medium every 3 days, and colonies of at least four times as large as single cell were counted at day 21. Colony formation rate was calculated as colony number/seeding cell number × 100%. Triplicate independent experiment was done.

Tumor formation in nude mice was also performed with eIF-5A2-transfected NIH3T3 cells and LO2 cells. Each animal received single injection of 4 × 104 cells suspended in 0.2 ml of PBS. NIH3T3 or LO2 cells transfected with empty vector were injected on the left dorsal flank, and eIF5A2-transfected NIH3T3 or LO2 cells were injected on the right dorsal flank of the same animal. The animals were examined for tumor formation over a period of 1 month.

Reduction of Double Minutes (DMs) in UACC-1598. Ovarian cancer cell lines UACC-1598 were obtained from the Tissue Culture Core Service of the University of Arizona Comprehensive Cancer Center. UACC-1598 cells were grown in DMEM with 10% fetal bovine serum and exposed to 50 μM hydroxyurea (HU) for 30 cell doublings and 100 μM HU for 20 cell doublings, respectively. The parental UACC-1598 cell was used as a control. Genomic DNA was prepared, and the eIF-5A2 copy number was determined by Southern blot analysis. The amount of total DNA was internally controlled by PhosphorImager (Molecular Dynamics, Sunnyvale, CA) and compared with the control to yield relative percent. Expression of EIF-5A2 was also analyzed by Northern blot hybridization, 28S and 18S rRNA in separating gel stained with ethidium bromide for the Northern blot were used as loading control.

To test cell growth rate, the HU-treated cells were washed, grown without HU for 48 h, and then seeded onto 24-well plate at a density of 1 × 104 cells/well and incubated for 1–7 days. The cell growth rate of HU-treated cells was compared with parental UACC-1598 cells using cell proliferation 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt kit (Roche, Mannheim, Germany) according to manufacturer’s instructions.

Received 12/2003; revised 3/22/04; accepted 4/6/04.

Grant support: Research Grant Council Grant HKU7287/02M and Leung Kwok Tze Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Xin-Yuan Guan, Department of Clinical Oncology, University of Hong Kong, Room 109, School of Chinese Medicine Building, 10 Sassoon Road, Hong Kong, People’s Republic of China. E-mail: xyguan@hkacc.hku.hk.

4197

Downloaded from cancerres.aacrjournals.org on July 19, 2017. © 2004 American Association for Cancer Research.
Antisense DNA against elf-5A2. elf-5A2 was cloned into pcDNA3.1(+ vector in an antisense orientation. Approximately $2 \times 10^7$ UACC-1598 cells in a T25 flask were transfected with 12 μg of pcDNA3.1(+) vector containing AS-elf-5A2 overnight using Lipofectamine (Life Technologies, Inc.) according to the manufacturer’s instructions. After transfection, UACC-1598 cells were seeded onto 96-well plate at a density of $2 \times 10^3$ cells/well and incubated for 1–7 days. The cell proliferation rate of transfected cells was compared with the parental cell using cell proliferation 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]–2H-tetrazolium–5-carboxanilide inner salt kit (Roche) according to manufacturer’s instructions.

Southern, Northern, and Western Blot Analyses. For Southern blot analysis, 10 μg of genomic DNA were digested with EcoRI, fractionated on 1% agarose gel, transferred to a nylon membrane, and hybridized with $^{32}$P-labeled probes. For Northern blot analysis, 15 μg of total cellular RNA were size fractionated on 1% agarose/2.2 M formaldehyde gel, transferred to a nylon membrane, and hybridized with $^{32}$P-labeled probes. For Western blotting, 30 μg of protein extract were resolved by 10% SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride Hybond-P membrane (Amersham Pharmacia Biotechnology, Piscataway, NJ) by electroblotting. After blocking, the blot was probed with antibody, followed by treatment with secondary antibody. Immunoreactions were visualized by enhanced chemiluminescence according to the manufacturer’s menu (Amersham Pharmacia Biotechnology).

Tissue Microarray (TMA) and Immunohistochemical Staining. For the construction of ovarian cancer TMA, the tumor cases encompassed 240 cases with histologically confirmed epithelial ovarian cancers from Cancer Institute, Sun Yat-Sen University (Guangzhou, People’s Republic of China). The TMA was constructed as described previously (19). Briefly, a TMA instrument (Beecher Instruments, Silver Spring, MD) was used to create holes in a recipient paraffin block to obtain cylindrical core tissue biopsy samples with a diameter of 0.6 mm from all ovarian cancers and to transfer these biopsy samples to the recipient block at defined array positions. Two samples were selected from each case. Multiple sections (5-μm thick) were cut from the TMA block and mounted on microscope slides.

Immunohistochemistry study was performed using the standard streptavidin-biotin-peroxidase complex method. Antigen retrieval was performed by treating the slide in 10 mM citrate buffer (pH 6.0) in a microwave for 5 min. A 1:2000 diluted polyclonal anti-elf-5A2 (SAGE BioVentures, San Diego, CA) antibody was used for elf-5A2 detection. Negative control was performed by replacing the primary antibody with blocking serum.

**RESULTS**

Tumorigenic Ability of elf-5A2. The tumorigenic ability of elf-5A2 was studied by anchorage-independent growth in soft agar and tumor formation in nude mice. elf-5A2 was cloned into expression vector pcDNA3.1(+) and then transfected into NIH3T3 and human liver cell line LO2. The expression level of elf-5A2 in transfected NIH3T3 and LO2 cells was determined by Northern blot hybridization (Fig. 1, A and B). Soft agar assay showed that elf-5A2 could obviously increase the colony formation in soft agar in both NIH3T3 and LO2 cells (Fig. 1, C and D). Tumor formation in nude mice was also performed with elf-5A2-transfected NIH3T3 and LO2 cells. The result was summarized in Table 1. Elf-5A2-expressing NIH3T3 cells could not cause tumor formation in nude mice. However, Elf-5A2-expressing LO2 cells exhibited strong tumor formation ability in nude mice. In all eight nude mice that received injections of Elf-5A2-expressing LO2 cells, the tumor appeared in 10–14 days, and the tumor volume ranged from 118 to 1015 mm$^3$ after 1 month (Fig. 1, E and F, and Table 1). Tumor formation was also observed in 3 of 8 empty vector-transfected LO2 cells with tumor volume 11–32 mm$^3$.

To confirm whether the tumor formation in nude mice was caused by elf-5A2 transfection, expression of elf-5A2 in both tumors induced by elf-5A2-expressing LO2 and vector-transfected LO2 cells was examined by anti-Elf-5A2 antibody. Cytoplasmic expression of Elf-5A2 was detected in all tumors induced by elf-5A2-expressing LO2 cells but not in tumors induced by vector-transfected LO2 cells (data not shown).

**Fine Mapping DMs in UACC-1598.** High copy number amplification of elf-5A2 has been detected in an ovarian cancer cell line UACC-1598 in the form of DMs (12). To identify all possible amplified genes within the amplicon, a bacterial artificial chromosome contig covering the 3q26.2 region was established by NCBI BLAST search. Boundaries of the amplicon were determined by Southern blot hybridization using DNA sequences from bacterial artificial chromosome clone as probes (Fig. 2). The distance between boundaries (P2 and P3) of the amplicon is ~388 kb, and elf-5A2 was the only known

---

**Table 1 Tumorigenicity test of elf-5A2-expressing cells in nude mice**

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>No. tumor formation/ no. tested nude mice</th>
<th>Tumor volume (mm$^3$$^a$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH3T3</td>
<td>0/10</td>
<td></td>
</tr>
<tr>
<td>elf-5A2-NIH3T3</td>
<td>0/10</td>
<td></td>
</tr>
<tr>
<td>Vector-LO2</td>
<td>0/10</td>
<td></td>
</tr>
<tr>
<td>elf-5A2-LO2</td>
<td>8/8</td>
<td>m1: 18; m2: 11; m5: 32</td>
</tr>
<tr>
<td></td>
<td></td>
<td>m1: 219; m2: 242; m3: 319; m4: 1015; m5: 167; m6: 319; m7: 118; m8: 292</td>
</tr>
</tbody>
</table>

$^a$Tumor volume (V) was estimated from the length (l) and width (w) of the tumor using the formula: $V = (\pi w) \times (l + w)/2$. Tumor volume of each nude mouse is listed.
A gene within the amplicon based on BLAST search. Two predicted genes (LOC402149 and LOC2000916) were found within the amplicon (Fig. 2). To evaluate the expression level of these two predicted genes, reverse transcription-PCR was used to amplify these two genes. However, no PCR product was obtained.

**Inhibition of Cell Growth by Reducing DMs.** To determine whether the amplification of eIF5-A2 could accelerate cell proliferation like eIF-5A, the correlation of reduction of eIF-5A2 copy number and cell growth rate was studied. Low concentration of HU was added into the culture medium to reduce the DMs in UACC-1598 because HU can eliminate extrachromosomal DMs in culture cells (20). After 20 passages of exposure to 100 μM and 30 passages to 50 μM HU, the copy number of eIF5A2 was reduced to 78 and 45%, respectively, compared with those in the parental UACC-1598 cells (Fig. 3A). The expression of EiF-5A2 was also reduced to 66 and 30%, respectively, compared with those in the parental cells (Fig. 3A). Cell growth assay showed that reduction of DMs containing eIF-5A2 in UACC-1598 led to a decreased cell growth rate in vitro (Fig. 3B).

**Inhibition of Tumor Cell Growth by Antisense DNA against eIF-5A2.** Full-length antisense DNA sequence against eIF-5A2 was cloned into expression vector pcDNA3.1(+) and then transiently transfected into UACC-1598 cells. Western blot analysis showed that the expression of EiF-5A2 was effectively blocked by AS-eIF-5A2 (Fig. 3C). Relative to β-actin, expression of EiF-5A2 in UACC-1598 cells transfected with AS-eIF-5A2 was decreased 80% compared with that in the parental UACC-1598 cells. As a result, the cell growth rate of UACC-1598 cells transfected with AS-eIF-5A2 was obviously decreased compared with the parental UACC-1598 cells (Fig. 3D).

**Correlation of EiF-5A2 Overexpression and Clinical Features of Ovarian Cancer.** The correlation of EiF-5A2 overexpression and clinical features of ovarian cancer was studied by TMA with 240 epithelial ovarian cancers. Using immunohistochemical staining with anti-EiF-5A2 antibody, informative staining was observed in 211 of 240 (88%) cases. The noninformative samples included lost samples, unrepresentative samples, and samples with too few tumor cells. On the basis of the staining density, cytoplasmic expression of EiF-5A2 could be divided into negative, weak, moderate, and strong. Because moderate and strong expression of EiF-5A2 could not be observed in 7 normal ovary (not included in TMA), negative/weak and moderate/strong staining were defined as normal expression and overexpression, respectively. Normal expression and overexpression of EiF-5A2 were detected in 89 (42.2%) cases and 122 cases (57.8%), respectively. The association between EiF-5A2 expression and clinical features of ovarian cancer, including patient’s age, tumor histological type, and tumor’s Silverberg grade, was analyzed. A significant association between EiF-5A2 overexpression and tumor’s International Federation of Gynecology and Obstetrics stage was observed. The frequency of overexpression of EiF-5A2 in advanced International Federation of Gynecology and Obstetrics stages (III and IV; 85 of 123, 69.1%) was significantly higher than that in earlier stages (I and II) (37 of 88, 42.0%; P < 0.001, Fisher’s exact test). Fig. 4 shows the examples of normal expression of EiF-5A2 in normal ovary and overexpression of EiF-5A2 in ovarian cancer. No significant association was found between EiF-5A2 overexpression and other clinical features.

**DISCUSSION**

Amplification of 3q26 is one of the most frequent chromosomal alterations in ovarian cancer, lung cancer, esophageal cancer, prostate cancer, breast cancer, and nasopharyngeal cancer, suggesting an oncogene(s) localized in this region playing important roles in carcinogenesis. Recently, one candidate oncogene eIF-5A2, which shares 82% amino acid sequence with eIF-5A, has been isolated from 3q26.2. A number of studies have shown the involvement of EiF-5A in cell growth, cell proliferation, and against apoptosis (13–16). As the result of its similarity to EiF-5A, it is highly possible that EiF-5A2 may also play important roles in carcinogenesis.

In the present study, the oncogenic role of eIF-5A2 was supported...
by the following evidence: (a) cell growth in ovarian cancer cell line UACC-1598 was inhibited when eIF-5A2 expression level was decreased by reducing the copy number of DMs containing eIF-5A2; (b) treatment of UACC-1598 cells with AS-eIF-5A2 obviously decreased the cell growth; (c) anchorage-independent growth in soft agar was observed in eIF-5A2-transfected NIH3T3 and LO2 cells; (d) tumor formation in nude mice was induced in eIF-5A2-transfected LO2 cells; and (e) overexpression of eIF-5A2 was significantly associated with the advanced stages of ovarian cancer.

The size of amplicon of the DMs is ~388 kb and eIF-5A2 is the only known gene within the amplicon. It is possible that some other genes within the amplicon are amplified and related to the pathogenesis of ovarian cancer. On the basis of the BLAST search, at least two predicted genes have been mapped within the amplicon. Reverse transcription-PCR results showed that both genes could be pseudogenes.

Other than eIF-5A2, PIK3CA has been implicated as a candidate oncogene at 3q26 (21). Overexpression of PIK3CA has been also associated with the pathogenesis of cervical cancer and head and neck cancer (22, 23). It is possible that E5A2 may cooperate with PIK3CA to promote ovarian carcinogenesis. Better understanding of the physiological and pathophysiological functions of E5A2 may lead to a much more effective management of ovarian cancer with the amplification of the eIF-5A2, via early detection, precise prognostication, and molecularly targeted treatment.

REFERENCES

Oncogenic Role of eIF-5A2 in the Development of Ovarian Cancer

Xin-Yuan Guan, Jackie M-W. Fung, Ning-Fang Ma, et al.

Cancer Res 2004;64:4197-4200.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/12/4197

Cited articles
This article cites 22 articles, 7 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/12/4197.full#ref-list-1

Citing articles
This article has been cited by 13 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/64/12/4197.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.